Abstract
The hypothesis that non-erosive reflux disease (NERD) patients comprise various subgroups is gaining popularity. This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day. NERD patients were classified as grade N (endoscopically normal), M (minimal change), or erosive GERD, and answered a 51-item, yes-or-no questionnaire pre and post-treatment. Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD. Clinical significance of classifying NERD was indicated from different symptoms and responsiveness to PPI.
Similar content being viewed by others
References
Dent J, Brun J, Fendrick A, Fennerty M, Janssens J, Kahrilas P, Lauritsen K, Reynolds J, Shaw M, Talley N, The Genval Workshop Group (1999) An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut 44(Suppl 2):S1–16
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology 112:1798–1810
van Pixteren B, Numans ME, Bonis PA, Lau J (2006) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 19:CD002095
Tendler DA, Parker RA, Spechler SJ (1996) Heartburn: ethnic variations in prevalence and interpretation. Gastroenterology 110:A276
Fass R (2003) Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98(Suppl 3):S2–S7
Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD (1997) Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 11:755–763
Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, Omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease-in general practice. Scand J Gastroenterol 32:765–773
Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M (2004) Development and evaluation of FSSG; frequency scale for the symptoms of GERD. J Gastroenterol 39:888–891
Adachi K, Matsumori Y, Fujisawa T, Kamada T, Kusaka M, Ohumi T, Iwakiri R, Yamaguchi K, Danjo A, Hori K, Tomita T, Hayashi T, Haruma K, Fujimoto K, Miwa H, Kinoshita Y (2006) Symptom diversity of patients with reflux esophagitis: effect of omeprazole treatment. J Clin Biochem Nutr 39:46–54
Kahrilas PJ (2003) Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98(Suppl 3):S15–S23
Hoshihara Y (2004) Endoscopic findings of GERD. Nippon Rinsho 62:1459–1464
Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A (2005) Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 21:19–26
Hongo M (2006) Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 41:95–99
Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S (2002) Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Aliment Pharmacol Ther 97:1332–1339
Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL (2005) Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 11:3091–3098
Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J, Komazawa Y, Mihara T, Katsube T, Fujishiro H, Shizuku T, Hattori S, Yamamoto S, Kinoshita Y (2003) Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 18:1392–1398
Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators (2002) Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16:445–454
Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL (2002) A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16:479–485
Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Arakawa T (2005) Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 100:754–758
Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456
Lee KJ, Vos R, Janssens J, Tack J (2004) Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol 286:G278–G284
Jones RH, Baxter G (1997) Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 11:541–546
Jones RH, Crouch SL (1999) Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13:413–419
Joh T, Miwa H, Higuchi K, Shimatani T, Manabe N, Adachi K, Wada T, Sasaki M, Fujiwara Y, Hongo M, Chiba T, Kinoshita Y, ARS Research Group (2007) Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 42:444–449
Keohane J, Quigley EM (2006) Functional dyspepsia and non-erosive reflux disease: a review. Minerva Gastroenterol Dietol 52:261–267
Quigley EM (2004) Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 18:695–706
Suzuki H, Nishizawa T, Hibi T (2006) Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 41:513–523
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V (2006) Functional gastroduodenal disorders. Gastroenterology 130:1466–1479
Shimoyama Y, Kusano M, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Moki F, Sugiyama T, Toki M, Ohwada T, Mori M (2005) Diagnosis of gastroesophageal reflux disease using a new questionnaire. J Gastroenterol Hepatol 20:643–647
Acknowledgments
The study was supported by an unrestricted grant from Eisai Co., Ltd.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The authors of The Acid-Related Symptom (ARS) Research Group are given in Appendix I.
An erratum to this article can be found at http://dx.doi.org/10.1007/s10620-008-0636-9
Appendix I
Appendix I
The Acid-Related Symptom (ARS) Research Group consisted of the following investigators:
- Yoshikazu Kinoshita::
-
Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan.
- Michio Hongo::
-
Departments of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan.
- Tsutomu Chiba::
-
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Shuichi Ohara::
-
Health Administration Center, Department of Gastroenterology, Tohoku University Hospital, Sendai, Japan.
- Motoyasu Kusano::
-
Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Japan.
- Yoshio Hoshihara::
-
Clinic of the Ministry of Economy, Trade and Industry, Tokyo, Japan.
- Susumu Kurosawa::
-
The First Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
- Yusuke Watanabe::
-
Department of Otorhinolaryngology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
- Takahisa Furuta::
-
Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Takashi Joh::
-
Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Kazuhide Higuchi::
-
Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan.
- Yasuhiro Fujiwara::
-
Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
- Yasuki Habu::
-
Department of Gastroenterology, Saiseikai Noe Hospital, Osaka, Japan.
- Hiroto Miwa::
-
Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
- Ken Haruma::
-
Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.
- Noriaki Manabe::
-
Division of Endoscopy and Ultrasonography, Kawasaki Medical School, Kurashiki, Japan.
- Kyoichi Adachi::
-
Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, Japan.
- Tomohiko Shimatani::
-
Faculty of Nursing, Department of Nursing, Hiroshima International University, Kure, Japan.
- Masanori Ito::
-
Department of Medicine and Molecular Science, Hiroshima University, Hiroshima, Japan.
- Kazuma Fujimoto::
-
Department of Internal Medicine, Saga Medical School, Saga, Japan.
Rights and permissions
About this article
Cite this article
Kusano, M., Shirai, N., Yamaguchi, K. et al. It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients. Dig Dis Sci 53, 3082–3094 (2008). https://doi.org/10.1007/s10620-008-0290-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0290-2